Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medicenna Therapeutics Corp. has reported promising results from its ongoing ABILITY-1 study, showing significant efficacy of its MDNA11 treatment in combination with KEYTRUDA for challenging cancer types. The study highlights potential breakthroughs in treating cancers typically resistant to immunotherapy, with a 70-year-old patient achieving a complete response and demonstrating the potential of MDNA11 to enhance existing treatments.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.